GlassScriptPhysician profile
Paul Petersen
NPI 1245224336
$2,564.78
in general payments reported to CMS, 2019-2025
25 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $187 · 2021: $255 · 2022: $365 · 2023: $614 · 2024: $378 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,366.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $575.46 | 2019-2024 | |
| Janssen Biotech, INC. | $305.79 | 2021-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $236.59 | 2019-2025 | Xifaxan |
| Janssen Scientific Affairs, LLC | $184.66 | 2019-2023 | Stelara |
| Boston Scientific Corporation | $183.90 | 2020-2023 | Axios |
| Aimmune Therapeutics, INC. | $160.14 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.80 | 2019-2024 | Eohilia |
| Genzyme Corporation | $109.48 | 2022-2025 | |
| Gilead Sciences, INC. | $75.64 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $70.61 | 2021 | |
| Olympus America INC. | $70.26 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $69.33 | 2025 | Iqirvo |
| Qol Medical, LLC | $67.02 | 2019-2020 | |
| Madrigal Pharmaceuticals | $65.05 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $54.90 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $50.84 | 2023-2025 | Uplizna, Avsola, Amjevita |
| Intercept Pharmaceuticals, INC. | $35.58 | 2019-2021 | |
| Celgene Corporation | $33.35 | 2021-2023 | Zeposia |
| Fresenius Kabi USA, LLC | $18.94 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $16.70 | 2023 | Dupixent |
| Ironwood Pharmaceuticals, INC | $16.14 | 2023 | Linzess |
| Ferring Pharmaceuticals INC. | $16.06 | 2022 | |
| Pfizer INC. | $14.05 | 2024 | |
| Medtronic, INC. | $13.11 | 2022 | |
| Organon LLC | $11.38 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Petersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.